A Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of TAK-475 [lapaquistat] Alone or co-Administered With Atorvastatin in Subjects With Primary Dyslipidemia

Trial Profile

A Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of TAK-475 [lapaquistat] Alone or co-Administered With Atorvastatin in Subjects With Primary Dyslipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Lapaquistat (Primary) ; Atorvastatin
  • Indications Dyslipidaemias
  • Focus Adverse reactions; Registrational
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2009 Planned number of patients changed from 1800 to 2130.
    • 11 Sep 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top